MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$27,514K
Proceeds from issuance of
common stock through...
$6,454K
Proceeds from issuance of
common stock pursuant...
$243K
Proceeds from sales of
property and equipment
$12K
Net cash provided by
financing activities
$34,211K
Net cash provided by
(used in) investing...
$5K
Canceled cashflow
$7K
Net decrease in
cash, cash...
-$42,945K
Canceled cashflow
$34,216K
Stock-based compensation
expense
$6,713K
Accounts payable
$2,193K
Offering costs
recognized in other...
$2,046K
Non-cash lease expense
$1,164K
Impairment of long-lived
assets
$1,112K
Depreciation and
amortization expense
$1,056K
Other non-current
assets
-$707K
Purchases of property and
equipment
$7K
Net cash used in
operating activities
-$77,161K
Canceled cashflow
$14,991K
Other income, net
$8,082K
Net loss
-$75,801K
Change in fair value of
warrant liability
-$8,528K
Canceled cashflow
$8,082K
Accrued expenses and
other current...
-$4,374K
Prepaid expenses and
other current assets
$1,779K
Operating lease liability
-$1,670K
Total operating
expense
$83,883K
Back
Back
Cash Flow
source: myfinsight.com
Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. (JSPR)